Geron recently presented data from the ongoing Phase 1 of the clinical trial for its human embryonic stem cell-based therapy for patients with spinal cord injury, according to a company news release.
After treatment on the first two patients enrolled in the trial, the company reported no serious adverse events. The therapy contains 2 million cells per dose and is delivered by injection into the spine between seven and 14 days after surgery.
One patient has completed their 180 day follow-up and MRI shows no evidence of immune resistance to the therapy.
Read the release on Geron's trials.
Related Articles on Spinal Cord Injury:
AAOS: Spinal Cord Injury Patterns Among Children in ATV Accidents
UPMC Project Tests Brian Computer Interface in Spinal Cord Injury Patients
New Rule Predicts Patient's Ability to Walk After Spinal Cord Injury
After treatment on the first two patients enrolled in the trial, the company reported no serious adverse events. The therapy contains 2 million cells per dose and is delivered by injection into the spine between seven and 14 days after surgery.
One patient has completed their 180 day follow-up and MRI shows no evidence of immune resistance to the therapy.
Read the release on Geron's trials.
Related Articles on Spinal Cord Injury:
AAOS: Spinal Cord Injury Patterns Among Children in ATV Accidents
UPMC Project Tests Brian Computer Interface in Spinal Cord Injury Patients
New Rule Predicts Patient's Ability to Walk After Spinal Cord Injury